Column | A blood test for 50-plus cancers? One survivor is glad he took it.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 trends tracked about this subject — the full history, oldest to newest below.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Grail faces lingering reimbursement hurdles despite approaching a landmark FDA approval for its Galleri cancer blood test.
A multi-cancer early detection blood test draws investor enthusiasm and trial data coverage across major financial and health outlets.
FDA advisers are set to vote on Grail’s Galleri blood test, a potential breakthrough in early detection of multiple cancers.
Grail stock surges over 30 percent as the FDA reviews its multi-cancer early detection blood test.